Signaling Pathways in Pancreatic Cancer
Signaling Pathways in Pancreatic Cancer
复制标题
DOI：
10.1615/critreveukargeneexpr.v21.i2.20
复制
发表时间：
2011-01-01
影响因子：
1.6
通讯作者：
Korc, Murray
中科院分区：
文献类型：
--
作者：
Preis, Meir;Korc, Murray
胰腺导管腺癌 (PDAC) 是一种致命的恶性肿瘤，其特征是存在大量分子改变，包括主要和次要驱动突变、存在强烈的结缔组织增生，表现出大量增殖的胰腺星状细胞 (PSC) 和产生纤连蛋白和胶原的癌症相关成纤维细胞，以及产生促有丝分裂细胞因子的炎症细胞灶。本综述将重点关注酪氨酸激酶受体的信号传导，并简要描述转化生长因子β在这种恶性肿瘤中的作用。将讨论与特定途径相关的治疗干预的潜力。
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy characterized by a plethora of molecular alterations that include major and minor driving mutations, the presence of intense desmoplasia exhibiting numerous proliferating pancreatic stellate cells (PSC) and cancer-associated fibroblasts that produce fibronectin and collagens, and foci of inflammatory cells that produce mitogenic cytokines. This review will focus on signaling by tyrosine kinase receptors, and the role of transforming growth factor beta in this malignancy is described briefly. Potential for therapeutic interventions will be discussed in relation to specific pathways.